Cell Division Locus Control for Pluripotent Cell Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for controlling pluripotent cell-based therapies face challenges in ensuring safety due to risks of malignant growth and oncogenic properties, particularly with the herpes simplex virus—thymidine kinase (HSV-TK)/ganciclovir system being unreliable and other methods failing to consistently prevent unwanted cell growth and differentiation.
Innovation Solution
The introduction of a method involving genetic modification of animal cells with a cell division locus (CDL) using an ablation link (ALINK) system or an inducible exogenous activator of regulation of CDL (EARC) system, allowing for controlled proliferation through the use of inducers, ensuring safe and reliable elimination or inhibition of unwanted cell division.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HSV-TK/GCV negative selectable system is used to eliminate unwanted cell growth, then cell proliferation control is achieved, but the system is unreliable and may not consistently prevent malignant transformation
Solution Approach 1:
The invention divides the control system into two independent but complementary components: (1) a CDL-modified allele providing inducible control of cell division loci, and (2) a separate negative selectable marker system for eliminating unwanted cells. This segmentation allows each component to perform its specific function reliably without the limitations of the HSV-TK/GCV system alone.
Solution Approach 2:
The invention performs preliminary genetic modification by introducing the CDL-modified allele into cells before therapy. This advance preparation ensures that the cells have built-in control mechanisms activated only when needed, rather than relying on unreliable post-hoc elimination methods like HSV-TK/GCV.
2Adaptability or versatility
If pluripotent cells are used for cell-based therapies, then therapeutic potential is increased, but risk of malignant growth and teratoma formation increases
Solution Approach 1:
The invention applies preliminary anti-action by equipping pluripotent cells with control mechanisms (CDL-modified alleles and negative selectable markers) before they can potentially cause harm. The inducible control systems are prepared in advance to stop proliferation if malignant transformation occurs, and negative selectable markers enable elimination of unwanted cells before they form teratomas.
Solution Approach 2:
The invention introduces intermediary control elements (CDL-modified alleles and negative selectable markers) that mediate between the therapeutic potential of pluripotent cells and the risk of malignant growth. These intermediaries allow the cells to maintain their therapeutic capabilities while providing safety mechanisms to prevent harm.
3Ease of operation
If negative selectable markers are introduced into cells for controlling proliferation, then unwanted cell growth can be eliminated, but expression may be unreliable
Solution Approach 1:
The invention merges the negative selectable marker system with the CDL-modified allele system into an integrated control platform. This combination ensures that cells expressing the negative selectable markers also have the inducible CDL control mechanisms, providing redundant and reliable control over cell proliferation.
Solution Approach 2:
The invention changes the operational parameters of negative selectable markers by using inducible promoters (such as tetracycline-responsive or cre-lox systems) to control marker expression. This allows the markers to be expressed only when needed, improving reliability by preventing constitutive expression that could eliminate desired cells.
Data Source
AI summary
The present disclosure provides molecular tools, methods and kits for using cell division loci (CDLs) to control cell proliferation in animal cells. CDLs, as provided herein, are loci whose transcription product(s) are expressed during cell division. CDLs may be genetically modified, as described herein, to comprise a negative selectable marker and/or an inducible activator-based gene expression system, which allows a user to permit, ablate, and/or inhibit proliferation of the genetically modified cell(s) by adding or removing an appropriate inducer.